Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 9950

Next Previous
Drug Profile

HRS 9950

Alternative Names: HRS-9950

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antivirals; Small molecules
  • Mechanism of Action Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 22 Nov 2024 Chengdu Suncadia Medicine completes a phase-II trial in Hepatitis B (Treatment-experienced) in China (PO, Tablet) (NCT05905458)
  • 28 Jul 2023 Phase-II clinical trials in Hepatitis B (Treatment-experienced) in China (PO) (NCT05905458)
  • 15 Jun 2023 Chengdu Suncadia Medicine plans a phase II trial for Hepatitis B in August 2023 (PO,Tablet) (NCT05905458)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top